AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study

書誌詳細
主要な著者:	Dummer, R, Robert, C, Chapman, P, Sosman, J, Middleton, M, Bastholt, L, Kemsley, K, Cantarini, M, Morris, C, Kirkwood, J
フォーマット:	Journal article
出版事項:	2008

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
著者:: Gupta, A, 等
出版事項: (2013)

Author Correction: Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer
著者:: Jin-Hang Gao, 等
出版事項: (2022-03-01)

MEK1/2 blockade by AZD6244 (ARRY-142886) inhibits tumor growth and progression in an orthotopic human lung adenocarcinoma model with enhanced efficacy when combined with cediranib
著者:: Takahashi, O, 等
出版事項: (2009)

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
著者:: Kirkwood, J, 等
出版事項: (2012)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
著者:: Leijen, S, 等
出版事項: (2011)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
著者:: Leijen, S, 等
出版事項: (2011)

TMZ-BioShuttle – a reformulated Temozolomide
著者:: Waldemar Waldeck, Manfred Wiessler, Volker Ehemann, Ruediger Pipkorn, Herbert Spring, Juergen Debus, Bernd Didinger, Gabriele Mueller, Joerg Langowski, Klaus Braun
出版事項: (2008-01-01)

Radiosensitization of Glioma Cells by Temozolomide (TMZ): A Colony Formation Assay
著者:: Somayyeh Babaloui, 等
出版事項: (2022-02-01)

Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244
著者:: Sylwia Ammoun, 等
出版事項: (2010-01-01)

Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme—A Literature Review and Clinical Outcomes
著者:: Marcin Jezierzański, 等
出版事項: (2024-07-01)

Resistance to Selumetinib (AZD6244) in Colorectal Cancer Cell Lines is Mediated by p70S6K and RPS6 Activation
著者:: Silvina Grasso, 等
出版事項: (2014-10-01)

miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)
著者:: Zongze He, 等
出版事項: (2022-10-01)

Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
著者:: Jun-Hai Tang, 等
出版事項: (2019-12-01)

Concomitant treatment of brain metastasis with Whole Brain Radiotherapy [WBRT] and Temozolomide [TMZ] is active and improves Quality of Life
著者:: Montella Liliana, 等
出版事項: (2007-01-01)

Long-term Temozolomide Treatment Induces Marked Amino Metabolism Modifications and an Increase in TMZ Sensitivity in Hs683 Oligodendroglioma Cells
著者:: Delphine Lamoral-Theys, 等
出版事項: (2010-01-01)

Co-administration of temozolomide (TMZ) and the experimental therapeutic targeting miR-10b, profoundly affects the tumorigenic phenotype of human glioblastoma cells
著者:: Ming Chen, 等
出版事項: (2023-06-01)

Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
著者:: Paul Lesueur, 等
出版事項: (2019-03-01)

Transcriptomic analysis identifies the neuropeptide cortistatin (CORT) as an inhibitor of temozolomide (TMZ) resistance by suppressing the NF-κB-MGMT signaling axis in human glioma
著者:: Zongze He, 等
出版事項: (2024-05-01)

TRPC5 mediates TMZ resistance in TMZ-resistant glioblastoma cells via NFATc3-P-gp pathway
著者:: Yan Zou, 等
出版事項: (2021-12-01)

Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
著者:: Ranson, M, 等
出版事項: (2007)

Computer interfacing with radial line slot arry (RLSA) antenna measurement /
著者:: 254621 Chin, Wen Sing
出版事項: (1999)

Monitoring and quantification of rural urbanisation: Case of Arris and Theniet Elabed, Algeria
著者:: Soto Sabrina, 等
出版事項: (2024-01-01)

In search of an architectural genome of traditional houses: Case of the habitat of the Dechras of Arris
著者:: Aksas Samiha, 等
出版事項: (2023-01-01)

581 Final analysis of 2-THE-TOP: a phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma
著者:: David Tran, 等
出版事項: (2023-11-01)

High-Resolution Flow Cytometry: a Suitable Tool for Monitoring Aneuploid Prostate Cancer Cells after TMZ and TMZ-BioShuttle Treatment
著者:: Klaus Braun, Volker Ehemann, Manfred Wiessler, Ruediger Pipkorn, Bernd Didinger, Gabriele Mueller, Waldemar Waldeck
出版事項: (2009-01-01)

Fingerprint-fingervein multimodal biometric authentication system on field programmable gate arry /
著者:: Chong, Yew Hoe, 1992-, 等
出版事項: (2015)

A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.
著者:: Kefford, R, 等
出版事項: (2009)

The Application of ATR Kinase Inhibitor AZD6738 in Combination with Radiotherapy for the Treatment of Melanoma
著者:: Maryam Talebpoor, 等
出版事項: (2022-06-01)

Dual axis rotation solar irradiance tracking system for photovoltaic arry [electronic resource] /
著者:: Thanikaikumaran R. Kuppusamy, 1987-, author 646957, 等
出版事項: (2017)

The phenomenon of repetition according to Abu Al-Ala’ Al-Ma’arri in “The Chapters and Ends”
著者:: زهره قرباني مادواني
出版事項: (2018-02-01)

IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide
著者:: Ramcharan, R, 等
出版事項: (2015)

Conce pts of statistical inference/
著者:: 216135 Guenther, William C.
出版事項: (1973)

Fingerprint-fingervein multimodal biometric authentication system on field programmable gate arry [electronic resource] /
著者:: Chong, Yew Hoe, 1992-, 等
出版事項: (2015)

An optical wavelength multi/demultiplexing (DWDM/CWDM) based arry waveguide grating (AWG) technique /
著者:: 333366 Ismahayati Adam, 等
出版事項: (2008)

KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells
著者:: Woessner Richard, 等
出版事項: (2009-07-01)

637 INB-200: Phase I study of gene modified autologous gamma-delta (γδ) T cells in newly diagnosed glioblastoma (GBM) patients receiving maintenance temozolomide (TMZ): immunobiologic correlative data
著者:: Trishna Goswami, 等
出版事項: (2023-11-01)

Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma
著者:: Yinghao Lu, 等
出版事項: (2024-01-01)

<b>Peroxidase activity in <em>Spondias dulcis</em></b> - 10.4025/actascitechnol.v32i4.6244
著者:: Dayse Pereira Barbosa Souza, 等
出版事項: (2010-12-01)

Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
著者:: Gogas, H, 等
出版事項: (2006)

Effects of temozolomide on tumor mutation burden and microsatellite instability in melanoma cells
著者:: M. Sawada, 等
出版事項: (2024-01-01)

AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study

類似資料

類似資料